Core Viewpoint - WuXi Biologics (02269) has seen a significant stock price increase, with a rise of over 6%, currently trading at HKD 43.72, with a transaction volume of HKD 878 million [1] Financial Performance - WuXi Biologics has released a performance forecast, expecting a revenue growth of approximately 16.7% to RMB 21.79 billion for 2025 [1] - The company's net profit attributable to shareholders is projected to increase by 46.3% to RMB 4.908 billion [1] - Adjusted profit is anticipated to grow by 22.0% to RMB 6.586 billion [1] - Gross margin is expected to improve to 46.0%, an increase of about 5 percentage points year-on-year [1] Analyst Insights - Citi has published a report indicating that WuXi Biologics has issued an earnings upgrade for the second half of 2025, with revenue expected to grow by 17% year-on-year, aligning with market expectations [1] - Adjusted net profit is forecasted to increase by 31% to RMB 3.7 billion, significantly exceeding market expectations [1] - The gross margin is projected to rise by 6.2 percentage points to 48.8%, which is highlighted as a key positive surprise in the earnings upgrade and a major driver of better-than-expected profitability [1] - WuXi Biologics remains a preferred stock in the Chinese CRO and CDMO industry according to the report [1]
港股异动 | 药明生物(02269)再涨超6% 去年下半年经调整纯利远胜预期 毛利率显著增长